Reaction
Bronchopulmonary Dysplasia reporting signals
As of the last recalculation, Bronchopulmonary Dysplasia appears in 792 FAERS reports alongside 23 co-occurring drug terms. The strongest observed disproportionality signal is PALIVIZUMAB (PRR 147.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Palivizumab | 78 | 147.9 | 148.7 |
| Indomethacin | 38 | 79.1 | 79.3 |
| Ampicillin | 19 | 61.7 | 61.9 |
| Ampicillin Sodium | 19 | 61.7 | 61.9 |
| Norepinephrine | 17 | 42.7 | 42.8 |
| Norepinephrine Bitartrate | 17 | 31.7 | 31.7 |
| Zidovudine | 15 | 30.0 | 30.1 |
| Magnesium Sulfate In Water For | 13 | 27.2 | 27.2 |
| Magnesium Sulfate Heptahydrate | 13 | 26.6 | 26.7 |
| Magnesium Sulfate | 13 | 26.6 | 26.6 |
| Labetalol | 11 | 22.0 | 22.0 |
| Rocuronium Bromide | 9 | 20.3 | 20.3 |
| Raltegravir | 12 | 19.4 | 19.4 |
| Sildenafil Powder, | 24 | 18.2 | 18.3 |
| Methoxy Polyethylene Glycol-Epoetin Beta | 7 | 16.8 | 16.8 |
| Meropenem | 20 | 16.8 | 16.8 |
| Progesterone | 14 | 16.4 | 16.4 |
| Epoprostenol | 7 | 14.2 | 14.2 |
| Bosentan | 26 | 14.0 | 14.0 |
| Atazanavir | 7 | 12.9 | 12.9 |
| Micafungin Sodium | 4 | 12.5 | 12.5 |
| Remdesivir | 5 | 9.9 | 9.9 |
| Vigabatrin | 4 | 7.2 | 7.2 |